An Attractive IP Portfolio Centered on Ear Diseases
Our lead drug development program is aimed at treating sensorineural hearing loss by regenerating lost inner ear hair cells. The goal of the drug development program is to obtain safety and clinical proof of concept data with a proprietary gamma-secretase inhibitor licensed from Eli-Lilly. The clinical study is done within an EU Horizon2020 funded consortium (REGAIN).
We are interested in expanding and developing our IP portfolio with preclinical stage assets for the treatment of inner and middle ear diseases.
If you are developing new treatments for inner and middle ear diseases, please contact us to discuss potential partnerships aimed at bringing new and better treatments to patients.